Literature DB >> 8749886

Clozapine: efficacy and safety.

R W Buchanan1.   

Abstract

Clozapine (Clozaril) represents the first major advance in the pharmacological treatment of schizophrenia since the introduction of antipsychotics into clinical practice in the 1950s. Studies consistently support its efficacy for reducing positive symptoms in acutely psychotic patients and in treatment-resistant patients, for preventing positive symptom exacerbations as a maintenance treatment, and for reducing symptoms of hostility and violence. There is evidence to suggest that clozapine may improve social and occupational functioning and quality of life and may reduce affective symptoms, hospitalizations, secondary negative symptoms, and tardive dyskinesia. Its most significant side effects include agranulocytosis, seizures, weight gain, hypotension and tachycardia, sedation, and perhaps rebound psychosis (with abrupt discontinuation of medication).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749886     DOI: 10.1093/schbul/21.4.579

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  17 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 3.  State of the science on psychosocial interventions for ethnic minorities.

Authors:  Jeanne Miranda; Guillermo Bernal; Anna Lau; Laura Kohn; Wei-Chin Hwang; Teresa LaFromboise
Journal:  Annu Rev Clin Psychol       Date:  2005       Impact factor: 18.561

Review 4.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

5.  Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.

Authors:  K van der Weide; H Loovers; K Pondman; J Bogers; T van der Straaten; E Langemeijer; D Cohen; J Commandeur; J van der Weide
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 6.  Improving treatment for persons with schizophrenia.

Authors:  A F Lehman
Journal:  Psychiatr Q       Date:  1999

7.  Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal.

Authors:  Niko Seppälä; Carita Kovio; Esa Leinonen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 9.  The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia.

Authors:  Josep Maria Haro; Luis Salvador-Carulla
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes.

Authors:  Michael E Cahill; Zhong Xie; Michelle Day; Huzefa Photowala; Maria V Barbolina; Courtney A Miller; Craig Weiss; Jelena Radulovic; J David Sweatt; John F Disterhoft; D James Surmeier; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.